menu
    • menu
    [{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ ChemomAb","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ ChemomAb"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Merger","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ ChemomAb","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ ChemomAb"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Anchiano Therapeutics, Inc

    Menu

    Anchiano Therapeutics, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anchiano Therapeutics, Inc

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Anchiano Therapeutics, Inc

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nebokitug

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : ChemomAb

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Chemomab Completes Merger with Anchiano Therapeutics

                            Details : Chemomab expects to use net proceeds from this private placement to advance in parallel three Phase 2 clinical trials for its lead product, CM-101, a novel antibody for treating rare fibrotic conditions, as well as to further develop its earlier-stage pi...

                            Product Name : CM-101

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 16, 2021

                            Lead Product(s) : Nebokitug

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : ChemomAb

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Anchiano Therapeutics, Inc

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Anchiano Therapeutics, Inc

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nebokitug

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Cormorant Asset Management

                            Deal Size : $45.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

                            Details : Financing will be used to advance the Chemomab pipeline. Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.

                            Product Name : CM-101

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 15, 2021

                            Lead Product(s) : Nebokitug

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Cormorant Asset Management

                            Deal Size : $45.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anchiano Therapeutics, Inc

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Anchiano Therapeutics, Inc

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nebokitug

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : ChemomAb

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement

                            Details : Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need.

                            Product Name : CM-101

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : Nebokitug

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : ChemomAb

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth